Thrombopoietin (THPO/TPO): Master Regulator of Megakaryopoiesis and Platelet Production via MPL/JAK2/STAT5 Signaling in Research

# Thrombopoietin (THPO/TPO): Master Regulator of Megakaryopoiesis and Platelet Production via MPL/JAK2/STAT5 Signaling in Research

Discovery and the Race to Clone the "Missing" Megakaryocyte CSF

The human THPO gene maps to chromosome 3q26-27 and encodes a 353-amino acid precursor with a 21-residue signal peptide, yielding a 332-amino acid mature secreted glycoprotein of ~70 kDa (due to extensive O-glycosylation). THPO has a unique two-domain architecture:

N-terminal erythropoietin-homology domain (EPO-HD, aa 1–153): Structurally homologous to EPO (despite only ~23% sequence identity), adopting a four-helical bundle fold (helices A–D) that mediates high-affinity MPL binding. This domain alone is biologically active, carrying full agonist potency at ~50% of full-length THPO. Three cysteines form two disulfide bonds (Cys7–Cys151; Cys29–Cys85) that are essential for structure and activity.

C-terminal carbohydrate-rich domain (aa 154–332): Contains extensive O-glycosylation (up to 6 O-linked sugar chains on Ser/Thr residues) and 4 N-glycosylation sites. This domain does not contribute to MPL binding but is critical for plasma stability, half-life extension (preventing proteolytic degradation), and bioavailability. Recombinant EPO-HD fragments without this domain have vastly reduced in vivo potency due to rapid clearance.

The primary source of circulating THPO is hepatocytes (constitutive production), with secondary contributions from renal proximal tubular cells, bone marrow stromal cells, and skeletal muscle. Unlike EPO, THPO synthesis is not regulated at the transcriptional level by thrombocytopenia — instead, plasma THPO levels are regulated primarily by receptor-mediated clearance: platelets and megakaryocytes express MPL, which internalizes and degrades THPO. When platelet counts are low (few MPL-bearing cells), THPO accumulates; when platelet counts are high, increased MPL-mediated clearance reduces free THPO. This elegant mass-action regulation was validated by the observation that aplastic anemia patients with absent megakaryocytes and platelets have massively elevated THPO levels, whereas reactive thrombocytosis patients have near-normal levels.

MPL Receptor Structure and Signaling Architecture

MPL (CD110) is encoded by MPL on chromosome 1p34 and encodes a 635-amino acid type I transmembrane glycoprotein. The extracellular domain contains two cytokine receptor homology (CRH) modules in tandem — each with the canonical WSXWS motif — creating a D1-D2 architecture that differs from most cytokine receptors, which have only one CRH domain. This duplication enables the high-affinity two-site binding mode: THPO Site I contacts D1, and THPO Site II contacts D2, creating a 2:2 THPO:MPL complex upon homodimerization.

Two MPL homodimers form a 2:2 complex upon THPO binding, activating constitutively associated JAK2 on each receptor chain through transphosphorylation. Activated JAK2 then phosphorylates multiple tyrosine residues in the MPL cytoplasmic tail, recruiting:

STAT5A/B (primary downstream effector): Phospho-STAT5 dimerizes, translocates to nucleus, and drives megakaryocytic transcription — BCL-XL (survival), cyclin D3 (G1/S), GATA1/FOG1 (megakaryocytic master TFs). STAT5 is the dominant proliferative signal in early megakaryocyte progenitors.

STAT3: Secondary signal, particularly relevant for emergency thrombopoiesis and HSC maintenance responses.

PI3K/AKT/mTOR: p85 recruitment via IRS-2 adaptor → AKT phosphorylation → FOXO3a exclusion (anti-apoptotic) + mTORC1 activation (translational control, cytoplasmic expansion during endomitosis).

MAPK/ERK: RAS→RAF→MEK→ERK1/2 cascade drives megakaryocyte proliferation, particularly at CMP/GMP→megakaryocyte-erythroid progenitor (MEP) stages.

SRC family kinases (SFKs): MPL cytoplasmic domain recruits SRC/LYN via non-phosphotyrosine mechanisms; SFK activation contributes to platelet activation signaling downstream of residual MPL on mature platelets.

Negative regulation: SOCS1/3 limit JAK2 via pseudosubstrate inhibition and ubiquitin-mediated degradation; SHP1/2 dephosphorylate JAK2 and STAT5; LNK (SH2B3) directly inhibits JAK2 by competing for phosphotyrosine docking — LNK loss-of-function mutations (W515L) confer JAK2-independent MPL activation in myeloproliferative neoplasms.

Megakaryopoiesis: From Bipotent Progenitor to Platelet-Shedding Megakaryocyte

TPO drives megakaryocytopoiesis through a hierarchical progenitor cascade: HSC → MPP → MEP → megakaryocyte progenitor (MkP) → immature megakaryocyte → mature polyploid megakaryocyte → proplatelets/platelets. Key THPO/MPL actions at each stage:

MEP → MkP commitment: THPO promotes GATA1 expression and suppresses PU.1, biasing MEP toward megakaryocytic versus erythroid fate. High THPO concentrations favor megakaryopoiesis; SCF (c-Kit/KITLG) cooperates with THPO to expand MkP numbers.

Endomitosis and polyploidization: Mature megakaryocytes undergo repeated rounds of DNA synthesis without cytokinesis (endomitosis), reaching ploidy of 64N–128N. THPO drives endomitosis via cyclin D3/CDK4-6 and selective inhibition of RhoA-ROCK-myosin II cytokinetic contractility. mTORC1 activation expands cytoplasmic volume proportionally. Each ploidy doubling increases platelet-shedding potential.

Proplatelet formation: Mature megakaryocytes extend long cytoplasmic processes (proplatelets) into bone marrow sinusoids; microtubule motor-driven fragmentation generates platelets in circulation. THPO itself is not required for this final step — it primarily expands the upstream progenitor pool. IL-11, IL-6, TPO act cooperatively; dematin/spectrin cytoskeletal reorganization is THPO-independent.

Normal platelet count regulation: ~150,000–400,000 platelets/µL maintained by 1×10¹¹ new platelets/day (10-day lifespan). THPO plasma concentration ~100 pg/mL at steady state; rises 10–100× in severe thrombocytopenia (particularly aplastic anemia/chemotherapy).

JAK2 V617F and MPL W515 Mutations: Oncogenic Hijacking of TPO Signaling

In ET and MF cases lacking JAK2 V617F, MPL exon 10 mutations (W515L, W515K, S505N) confer cytokine-independent MPL activation — typically found in ~5–10% of ET/MF. W515 normally maintains the receptor in an inactive monomeric state; W515L removes steric inhibition of spontaneous dimerization.

Calreticulin (CALR) mutations (type 1: 52-bp deletion; type 2: 5-bp insertion) in exon 9 are found in ~25–35% of ET/MF and generate a frameshift protein with a novel C-terminus that specifically activates MPL by binding its extracellular domain in the ER — a unique mechanism of cytokine receptor activation by a non-secreted protein (Klampfl et al., 2013, NEJM PMID: 24325356).

Ruxolitinib (JAK1/2 inhibitor) FDA-approved for MF (2011) and PV (2014) directly targets the V617F JAK2 driving MPN; fedratinib and pacritinib provide additional JAK2-selective options, particularly in cytopenias.

Congenital Amegakaryocytic Thrombocytopenia (CAMT)

CAMT is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in MPL, resulting in absent megakaryocytes, severe thrombocytopenia from birth, and progressive aplastic anemia within the first decade due to HSC depletion. Endogenous THPO is massively elevated (10–100× normal) due to absent MPL-mediated clearance. CAMT is classified into two types: Type I (null mutations, severe) progresses rapidly to aplastic anemia; Type II (hypomorphic mutations, milder initial course) may have transient recovery before aplasia.

Hematopoietic stem cell transplantation (HSCT) is curative. The dramatic HSC phenotype of CAMT directly validated the Thpo/Mpl HSC maintenance role first demonstrated in mouse knockouts — rare human genetics confirming mouse models.

Recently, biallelic THPO gene mutations have also been identified as a cause of CAMT, confirming the ligand is as essential as the receptor for HSC maintenance (Spinner et al., 2022 reports). This ligand-based CAMT responds to exogenous recombinant THPO mimetics.

Thrombopoietin Receptor Agonists (TPO-RAs) in Research and Therapy

First-generation recombinant THPO (rhTPO) and a truncated PEGylated form (PEG-rHuMGDF) entered clinical trials for chemotherapy-induced thrombocytopenia but were withdrawn when a subset of patients developed neutralizing antibodies that cross-reacted with endogenous THPO, causing severe aplastic thrombocytopenia. This immunogenicity crisis — caused by the antibodies recognizing both recombinant and native THPO — forced development of non-peptide or peptide mimetics with no sequence homology to native THPO:

Eltrombopag (Promacta/Revolade): A small molecule thrombopoietin receptor agonist — a bis-arylhydrazone orally bioavailable compound that binds the MPL transmembrane domain at a site completely distinct from the extracellular THPO/romiplostim binding site, inducing receptor conformational changes that activate JAK2 without competing with endogenous THPO. Eltrombopag also chelates zinc ions in the gastrointestinal tract (affecting absorption of divalent cation co-medications) and has direct anti-apoptotic effects in megakaryocytes independent of MPL. FDA approved November 2008 for ITP; subsequently approved for aplastic anemia (2014) and HCV-associated thrombocytopenia. Oral administration (once daily, fasting requirement due to polyvalent cation binding) distinguishes it from parenteral romiplostim.

Avatrombopag (Doptelet): Second oral TPO-RA (thienopyrimidine class), approved 2018/2019 for ITP and thrombocytopenia in chronic liver disease (CLD) prior to procedures. Unlike eltrombopag, avatrombopag lacks the zinc-chelating motif and can be taken with food; no liver-specific dosing concerns. Acts at the same MPL transmembrane site as eltrombopag.

Lusutrombopag (Mulpleta): Third oral TPO-RA, approved 2018 for thrombocytopenia in CLD prior to invasive procedures. Similar mechanism to avatrombopag.

Hetrombopag: TPO-RA approved in China for aplastic anemia and ITP.

Research Applications of TPO/MPL Biology

Ex Vivo Megakaryocyte Differentiation and Platelet Production

Recombinant THPO is the cornerstone reagent for ex vivo megakaryocyte differentiation from CD34+ HSCs or iPSCs. Standard protocols use THPO (50–100 ng/mL) ± SCF ± IL-11 ± IL-3 over 7–14 days to generate megakaryocytes in suspension culture or fibronectin-coated bioreactors. High-shear flow bioreactors mimicking sinusoidal hemodynamics maximize proplatelet formation and platelet yield. Research groups have generated functional "designer platelets" from iPSC-derived megakaryocytes with enhanced antigen expression (HLA-deleted, HPA-1a-positive) for transfusion-compatible products — a research frontier motivated by platelet alloimmunization and inventory challenges.

Aplastic Anemia Bone Marrow Research

ITP Pathophysiology Research

ITP is characterized by immune-mediated platelet destruction AND impaired megakaryocyte differentiation — anti-platelet antibodies (anti-GPIIb/IIIa, anti-GPIb/IX) also target megakaryocyte surface antigens, impairing proplatelet formation. THPO levels in ITP are paradoxically low-to-normal despite thrombocytopenia, because abundant antibody-coated platelets retain sufficient MPL capacity to clear THPO. TPO-RA responses in ITP thus reflect both increased megakaryocyte output and partial override of anti-megakaryocyte antibody effects.

MPN Disease Modeling

Mpl W515L and JAK2 V617F knock-in mouse models faithfully recapitulate MPN phenotypes — thrombocytosis, erythrocytosis, marrow fibrosis — and have been essential tools for validating JAK inhibitor target engagement and resistance mechanisms. CALR mutant knock-in mice (del52) develop ET-like disease, validating the CALR→MPL mechanism.

Research Tools and Experimental Models

Genetic Variants and Clinical Correlates

Beyond MPN driver mutations, THPO and MPL harbor clinically relevant germline variants:

MPL S505N: Activating germline mutation causes familial thrombocytosis (mild MPN phenotype); somatic S505N appears in MPN subsets. Distinguishes from acquired W515 mutations.

LNK (SH2B3) variants: SH2B3 is a physiological JAK2 inhibitor; loss-of-function LNK variants (E208Q, W262R) cause mild MPN and triple-negative ET (JAK2/MPL/CALR-negative ET).

Current Research Frontiers

iPSC-derived platelets: Clinical-grade manufacturing of transfusion platelets from iPSC-derived megakaryocytes using THPO + SCF + IL-11 + IL-1β protocols, with forced GATA1/FLI1/TAL1 overexpression to enhance megakaryocytic commitment. The primary research challenge is achieving sufficient proplatelet fragmentation yield; bioreactor designs mimicking sinusoidal shear stress are advancing.

TPO-RA in MDS/AML: THPO drives MDS megakaryocytes via MPL, and eltrombopag improves thrombocytopenia in lower-risk MDS. Concerns about AML stimulation in higher-risk MDS have led to careful clinical study design; the SUPPORT trial evaluated safety of romiplostim in lower-risk MDS.

Combination with immunosuppression in AA: Standard AA therapy (anti-thymocyte globulin + cyclosporine) combined with eltrombopag improved complete response rates from ~30% to ~58% in a landmark NEJM trial (Townsley 2017), establishing the combination as first-line for severe AA. Mechanistic question of whether eltrombopag works via MPL on residual HSCs or non-MPL pathways continues to generate research.

CALR mutant-specific targeting: Because mutant CALR uniquely activates MPL by direct binding of its novel C-terminus to the MPL extracellular domain, antibodies targeting the CALR mutant C-terminus (not present in wild-type CALR) are in development as MPN-specific therapies — a remarkable example of a neoantigen-like therapeutic target in MPN.

Platelet biology: Residual MPL on platelets participates in platelet activation, integrin αIIbβ3 (GPIIb/IIIa) activation, and P-selectin surface expression in response to THPO co-stimulation. This raises the question of whether THPO contributes to thrombosis risk in MPN beyond simple platelet number elevation — a clinically significant frontier given the high thrombotic morbidity in MPN.

Conclusion

Thrombopoietin and its receptor MPL constitute one of the most elegantly regulated cytokine-receptor axes in hematopoiesis — a mass-action feedback system where the very cells produced (platelets and megakaryocytes) serve as the clearance sink for their own growth factor. The simultaneous cloning by five groups in 1994 reflected the field-wide urgency to find this "missing" megakaryocyte CSF. Three decades later, THPO biology has yielded not only successful ITP therapies (romiplostim, eltrombopag, avatrombopag) and AA treatment (eltrombopag), but also a deep mechanistic understanding of MPN oncogenesis through JAK2 V617F, MPL W515L, and CALR mutations. The discovery that TPO-RAs expand HSCs in aplastic anemia — extending beyond their intended platelet-promoting role — exemplifies how fundamental hematopoietic research and clinical observation continue to illuminate each other through the lens of a single cytokine axis.

References

1. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533-538. PMID: 7915005

5. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA. 1998;95(3):1195-1200. PMID: 9448308

7. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. PMID: 15772651

9. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403. PMID: 18242413

10. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390. PMID: 24325356

---

FOR RESEARCH USE ONLY. Not for human or veterinary use. Not for diagnostic or therapeutic applications. All biological activity data are derived from in vitro and preclinical studies; results may not predict human clinical outcomes. Information is provided for educational and research purposes only.